2020
Immunological and Clinical Phenotyping in Primary Antibody Deficiencies: a Growing Disease Spectrum
Shin JJ, Liauw D, Siddiqui S, Lee J, Chung EJ, Steele R, Hsu FI, Price C, Kang I. Immunological and Clinical Phenotyping in Primary Antibody Deficiencies: a Growing Disease Spectrum. Journal Of Clinical Immunology 2020, 40: 592-601. PMID: 32239366, PMCID: PMC7260109, DOI: 10.1007/s10875-020-00773-y.Peer-Reviewed Original ResearchConceptsCommon variable immunodeficiencyInterstitial lung diseasePrimary antibody deficiencyConnective tissue diseaseAntibody deficiencyLow NK cell countHematopoietic malignanciesNon-infectious complicationsNon-infectious manifestationsNK cell countsNatural killer cellsPneumococcal vaccine responsesElectronic medical recordsResultsAll patientsImmune alterationsVaccine responsesKiller cellsTissue diseaseImmunoglobulin levelsVariable immunodeficiencyLung diseasePAD groupIgG deficiencyImmunological profileMedical records
2019
Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity
Brooks JP, Azmy V, Thompson A, Luon D, Prozora SD, Price C, Hsu FI. Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity. Journal Of Oncology Pharmacy Practice 2019, 26: 228-231. PMID: 30885040, DOI: 10.1177/1078155219836478.Peer-Reviewed Original ResearchConceptsOrthopedic malignanciesHypersensitivity reactionsEtoposide phosphatePediatric patientsEtoposide hypersensitivityLarge academic medical centerAcademic medical centerCase of etoposideContinued therapyChart reviewFurther therapyFirst dosesFull dosesEwing's sarcomaMedical CenterPatientsMalignancySafe alternativeEtoposideHypersensitivityTherapyDiphenhydramineDosesPremedicationSarcoma
2018
Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses
Romberg N, Le Coz C, Glauzy S, Schickel JN, Trofa M, Nolan BE, Paessler M, Xu M, Lambert MP, Lakhani SA, Khokha MK, Jyonouchi S, Heimall J, Takach P, Maglione PJ, Catanzaro J, Hsu FI, Sullivan KE, Cunningham-Rundles C, Meffre E. Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses. Journal Of Allergy And Clinical Immunology 2018, 143: 258-265. PMID: 29935219, PMCID: PMC6400323, DOI: 10.1016/j.jaci.2018.06.012.Peer-Reviewed Original ResearchConceptsCommon variable immunodeficiencyVariable immunodeficiencyB cellsCommensal bacteriaIsotype-switched memory B cellsRegulatory T cell frequencyFollicular helper T cellsGC responseIsotype-switched antibodiesT cell frequenciesSubset of patientsT cell compartmentHelper T cellsPeripheral blood samplesMemory B cellsGerminal center responseB cell clonesAutoimmune cytopeniasGC hyperplasiaSerum endotoxemiaExcisional lymphAntibody responseT cellsMucosal microbiotaSomatic hypermutation frequencies
2016
Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies
Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, Laidlaw T, Palis R, Legere H, Bunyavanich S, Breslow R, Wesemann D, Barrett N, Brennan P, Chong HJ, Liu A, Fernandez J, Fanning L, Kyin T, Cahill K, Bankova L, Lynch A, Berlin S, Campos S, Fuchs C, Mayer R, Matulonis U, Castells M. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. The Journal Of Allergy And Clinical Immunology In Practice 2016, 4: 497-504. PMID: 26895621, DOI: 10.1016/j.jaip.2015.12.019.Peer-Reviewed Original ResearchConceptsRapid drug desensitizationDrug desensitizationAllergic patientsLife expectancyMonoclonal antibodiesNonallergic control groupOptimal pharmacological agentsOverall health costsFirst-line therapyAdministration of carboplatinConnective tissue diseaseStandard of careIndividual patient reactionsDesensitized patientsNonallergic groupAllergic groupLine therapyRisk stratificationTissue diseaseHypersensitivity reactionsChronic diseasesOvarian cancerSevere reactionsNonsignificant increasePharmacological agents
2009
Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment
Brennan PJ, Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. Journal Of Allergy And Clinical Immunology 2009, 124: 1259-1266. PMID: 19910036, DOI: 10.1016/j.jaci.2009.09.009.Peer-Reviewed Original Research
2008
Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases
Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. Journal Of Allergy And Clinical Immunology 2008, 122: 574-580. PMID: 18502492, DOI: 10.1016/j.jaci.2008.02.044.Peer-Reviewed Original ResearchConceptsHypersensitivity reactionsRapid desensitizationLife-threatening hypersensitivity reactionMedical intensive care unitChemotherapeutic drugsRapid desensitization protocolRapid drug desensitizationIntensive care unitStandard of careFirst desensitizationTemporary tolerizationDesensitization protocolDrug desensitizationCare unitDrug allergensPreferred agentOutpatient settingIntraperitoneal routeSubsequent infusionLiposomal doxorubicinAllergic reactionsAlternative drugsInitial desensitizationTarget doseTreatment records
1998
Echocardiographic and surgical correlation of pericardial effusions in patients with malignant disease
Hsu F, Keefe D, Desiderio D, Downey R. Echocardiographic and surgical correlation of pericardial effusions in patients with malignant disease. Journal Of Thoracic And Cardiovascular Surgery 1998, 115: 1215-1216. PMID: 9605094, DOI: 10.1016/s0022-5223(98)70424-6.Peer-Reviewed Original Research